Summary & Overview
HCPCS Q5101: Injection, filgrastim-sndz (biosimilar), 1 microgram
HCPCS Level II code Q5101 denotes the injectable biosimilar filgrastim-sndz (Zarxio) at a unit strength of 1 microgram. This code is used to report the drug product itself when administered as a short-acting granulocyte colony-stimulating factor to prevent or treat neutropenia and support patients receiving myelosuppressive therapies. Nationally, biosimilar biologics such as filgrastim-sndz are important for cost management, formulary decisions, and access to supportive oncology care.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise overview of utilization and billing benchmarks, common billing practices for drug reporting, relevant policy updates affecting biosimilars and injectable biologics, and clinical context for when filgrastim-sndz is typically used.
Readers will learn the clinical purpose of Q5101, typical sites of service for administration, standard payer coverage considerations, and where to find related billing and policy guidance. Data not available in the input is clearly noted where applicable; the summary focuses on national implications, payer coverage landscape, and operational considerations for reporting this HCPCS Level II code.
Billing Code Overview
HCPCS Level II code Q5101 describes an injection of filgrastim-sndz, a biosimilar to filgrastim (Zarxio), dosed per 1 microgram. This code represents the billed supply or drug administration unit for the biosimilar product and is used when reporting the drug itself for a given quantity.
Service Type: Therapeutic biologic drug administration (short-acting granulocyte colony-stimulating factor biosimilar)
Typical Site of Service: Outpatient infusion or injection settings, including physician offices, outpatient clinics, and hospital outpatient departments
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old female receiving myelosuppressive chemotherapy for early-stage breast cancer presents to the outpatient oncology clinic for prophylactic neutropenia management. The oncology nurse prepares and administers Q5101 (injection, filgrastim-sndz, biosimilar, Zarxio, 1 microgram) subcutaneously, dosed per body weight or provider order, typically on days following chemotherapy to reduce risk of febrile neutropenia. The clinical workflow includes: medication verification and allergy review, calculation of total micrograms based on ordered dose (e.g., 300 mcg = 300 units of Q5101), aseptic preparation, patient education about injection-site reactions and fever monitoring, administration in the clinic or at home via trained caregiver instruction, documentation of lot number and administration site, and scheduling follow-up labs (CBC with differential) to assess neutrophil response prior to subsequent chemotherapy cycles.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When a portion of a single-use vial or syringe dose is discarded after preparation and documentation is required for billing split-dose wastage rules. |